SCHEMBL4073298

SCHEMBL4073298

Cc1cc(N(C)C)c2cc(N(c3ccc4nc(C)cc(N(C)C)c4c3)c3ncnc(-c4ccccc4)n3)ccc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.40
ADORA2A P29274 1/20 0.38
PSMB5 P28074 2/20 0.36
MET P08581 1/20 0.35
CYP1A2 P05177 3/20 0.34
MAPT P10636 3/20 0.34
TSHR P16473 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
HPGD P15428 2/20 0.34
CYP2C19 P33261 2/20 0.34
HIF1A Q16665 2/20 0.34
GLA P06280 1/20 0.34
CYP2C9 P11712 1/20 0.34
RECQL P46063 1/20 0.34
KDM1A O60341 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076923 0.82 TERT (0.50) TERTCYP1A2MAPTLMNAALDH1A1
SCHEMBL4081903 0.77 TERT (0.38) TERTCYP1A2MAPTLMNAALDH1A1
SCHEMBL4081856 0.75 TERT (0.36) TERT
SCHEMBL4074853 0.75 HRH4 (0.40) TERTCYP1A2MAPTTSHRSMN1; SMN2
SCHEMBL6593597 0.75 KDM4E (0.44) TERTMAPTSMN1; SMN2LMNAKDM4E
SCHEMBL4073596 0.74 POLB (0.41) TERTTSHRSMN1; SMN2KMT2AMEN1
SCHEMBL4073121 0.74 NTSR1 (0.36) TERTKMT2AMEN1
SCHEMBL4076921 0.74 TERT (0.40) TERTKDM1AKMT2A
SCHEMBL6593894 0.73 TERT (0.41) TERTCYP1A2MAPTTSHRSMN1; SMN2
SCHEMBL4077095 0.73 TERT (0.63) TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US claimed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US claimed
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS AVENTIS PHARMA S.A. (FR) 2009-09-10 US disclosed
US-7482352-B2 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2009-01-27 US disclosed
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US disclosed
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-03-31 US disclosed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent DNASE1L3, SERPINB1, BRDT TERT 43/4885ADORA2A 4119/4885PSMB5 1555/4885
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS DPYD, NTPCR, NME1 TERT 196/4885ADORA2A 3935/4885PSMB5 4001/4885
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents DPYD, NTPCR, NME1 TERT 196/4885ADORA2A 3935/4885PSMB5 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.